Цена акција Amylyx Pharmaceuticals Inc (AMLX) и новости

ПочетнаAMLX • NASDAQ

Amylyx Pharmaceuticals Inc

14,95 $

После радног времена:

14,85 $

(0,67%)-0,100

Затворено: 17. окт, 16:30:00 GMT-4 · USD · NASDAQ · Одрицање одговорности

Претходно закључено

15,17 $

Дневни опсег

14,40 $ - 15,25 $

Годишњи опсег

2,61 $ - 15,93 $

Тржишна вредност

1,59 млрд. USD

Просечна количина

2,10 мил.

Цена/зар.

Добит од дивиденди

Примарна размена

NASDAQ

Вести са тржишта

Naslovi.net

пре 14 сати

Akcije na američkoj berzi rastu: Evo šta je pozadina uspona Dau Džonsa i s&P 500

Yahoo

пре 1 сата

Is There Now an Opportunity in Dow After 6% Weekly Surge?

MSN

пре 57 минута

A get rich hack that's boringly beautiful

El-Balad.com

пре 8 минута

Dow Jones Futures: Tesla Earnings and China Talks Highlight Market Risks

Investor's Business Daily

пре 10 сати

S&P 500's New AI Play? Walmart In Buy Zone, Leads Five Stocks To Watch Amid Volatile Market

CNBC

пре 1 дана

Santoli's Friday market wrap-up: Firmer tone to end the week, as urgent regional bank selling abates

Основни подаци

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024. Wikipedia

Датум оснивања

2013

Веб-сајт

amylyx.com

Број запослених

123